# EPID Multiple Sclerosis Pregnancy Study

> **NCT02749396** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2089 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
- **DRUG:** Extavia (interferon beta-1b), Novartis Pharma AG
- **DRUG:** Rebif (interferon beta-1a), Merck Serono Europe Ltd
- **DRUG:** Plegridy (peginterferon beta-1a), Biogen Idec Ltd
- **DRUG:** Avonex (interferon beta-1a), Biogen Idec Ltd
- **DRUG:** MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
- **OTHER:** No MSDMDs therapy (control)

## Key facts

- **NCT ID:** NCT02749396
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-02
- **Primary completion:** 2018-08-14
- **Final completion:** 2018-08-14
- **Target enrollment:** 2089 (ACTUAL)
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02749396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02749396, "EPID Multiple Sclerosis Pregnancy Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02749396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*